NEOsphere Biotechnologies
Expertise Partner
NEOsphere Biotechnologies pioneers proteomics for TPD drug discovery. Our target and E3 ligase-agnostic high-throughput proteomic screening platform creates broad pipelines of novel degrader targets at scale and advances drug discovery at all stages. Cutting-edge mass spectrometry and expert data analysis characterize entire libraries of protein degraders in native cells and identify molecules acting through new E3 ligases and TPD mechanisms; global ubiquitinomics mechanistically validates degrader-induced modifications to an unparalleled depth.
PHARMARON
Event Partner
At Pharmaron, we're a leading contract research organisation known for our extensive laboratory services and expertise in Target Product Degradation (TPD). With advanced facilities and a dedicated team, we specialise in customised solutions for drug discovery and development. Our TPD capabilities allow for precise evaluation of drug stability and efficacy, ensuring the delivery of top-quality pharmaceuticals. With a track record of supporting over 2000 organisations globally, we've become a trusted partner in the biopharmaceutical field.
WuXi AppTec
Exhibition Partner
WuXi AppTec provides a full spectrum of services to support research focused on targeted protein degradation. Our discovery platform allows for in-depth biological and biophysical characterization of bifunctional molecules. We offer proximity assays to measure ternary complex formation, target protein ubiquitination and degradation assays, and high-resolution X-ray crystallography of binary and ternary complexes. Our platform also includes extensive chemistry services, such as custom synthesis, scale-up, and purification of new linkers and E3 ligase ligands.